Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
843 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07699939 | Perioperative HLX10 (Serplulimab) With S-1+Oxaliplatin (SOX) in Locally Advanced and PD-L1-Positive Gastric or Esophagogastric Junction Adenocarcinoma(PLATANUS) | recruiting | Phase 2 | 136 | National Cancer Center, JapanOTHER_GOV | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06644781 | A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | recruiting | Phase 3 | 510 | Daiichi SankyoINDUSTRY | 17 |
| Aug 4, 2026 |
| clinicaltrials |
| NCT06885034 | A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201) | recruiting | Phase 1 / Phase 2 | 451 | GlaxoSmithKlineINDUSTRY | 19 | Aug 3, 2026 | clinicaltrials |
| NCT07227402 | A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)(LITESPARK-033) | recruiting | Phase 3 | 904 | Merck Sharp & Dohme LLCINDUSTRY | 23 | Aug 3, 2026 | clinicaltrials |
| NCT01804686 | A Long-term Extension Study of PCI-32765 (Ibrutinib)(CAN3001) | recruiting | Phase 3 | 700 | Janssen Research & Development, LLCINDUSTRY | 30 | Jul 31, 2026 | clinicaltrials |
| NCT06055959 | A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis(ziMyG) | recruiting | Phase 2 / Phase 3 | 8 | UCB Biopharma SRLINDUSTRY | 5 | Jul 31, 2026 | clinicaltrials |
| NCT04831580 | A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer(ROCC) | recruiting | N/A | 840 | GOG FoundationNETWORK | 4 | Jul 30, 2026 | clinicaltrials |
| NCT06785818 | Long-term Follow up Local Registry Study of Kymriah in South Korea | recruiting | — | 500 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 30, 2026 | clinicaltrials |
| NCT07094113 | AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 434 | AmgenINDUSTRY | 14 | Jul 30, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT05827549 | Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia(ReCALL) | recruiting | Phase 2 | 90 | Ho Joon ImOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06099366 | Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in Children(SR ALL) | recruiting | Phase 2 | 116 | Hee Young JuOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06184009 | Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia(HR ALL) | recruiting | Phase 2 | 370 | Jae Wook LeeOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06257394 | Treatment of Pediatric Very High-risk Acute Lymphoblastic Leukemia in Korea(VHR ALL) | recruiting | Phase 2 | 74 | Hyoung Jin KangOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06516679 | Efficacy of Risk-Stratified Treatment in Newly Diagnosed Infant Leukemia | recruiting | Phase 2 | 40 | Yonsei UniversityOTHER | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07044336 | Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | recruiting | Phase 3 | 800 | AstraZenecaINDUSTRY | 28 | Jul 29, 2026 | clinicaltrials |
| NCT06161025 | A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 2 / Phase 3 | 860 | Daiichi SankyoINDUSTRY | 19 | Jul 28, 2026 | clinicaltrials |
| NCT07022483 | Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | recruiting | Phase 3 | 710 | Daiichi SankyoINDUSTRY | 13 | Jul 28, 2026 | clinicaltrials |
| NCT07527858 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | recruiting | Phase 2 | 170 | Gilead SciencesINDUSTRY | 4 | Jul 28, 2026 | clinicaltrials |
| NCT04951622 | A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | recruiting | Phase 3 | 199 | Janssen Research & Development, LLCINDUSTRY | 17 | Jul 27, 2026 | clinicaltrials |
| NCT05503797 | A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | recruiting | Phase 2 | 254 | Fore BiotherapeuticsINDUSTRY | 12 | Jul 27, 2026 | clinicaltrials |
| NCT05189639 | A Study To Learn About the Safety Medicine (Called Mylotarg) In People With Acute Myeloid Leukemia | recruiting | — | 165 | PfizerINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06699771 | Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies | recruiting | Phase 1 | 53 | GC Cell CorporationINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07460375 | A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 191 | LigaChem Biosciences, Inc.INDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
| NCT05882058 | DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | recruiting | Phase 2 | 204 | Boehringer IngelheimINDUSTRY | 12 | Jul 23, 2026 | clinicaltrials |
| NCT05253651 | A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer(MOUNTAINEER-03) | recruiting | Phase 3 | 400 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 25 | Jul 22, 2026 | clinicaltrials |
| NCT06072131 | To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL(CRESCENDO) | recruiting | Phase 3 | 504 | Acrotech Biopharma Inc.INDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT07441694 | Study of INCA036978 in Participants With Myeloproliferative Neoplasms | recruiting | Phase 1 | 218 | Incyte CorporationINDUSTRY | 11 | Jul 22, 2026 | clinicaltrials |
| NCT07634666 | Prediction of Myocardial Injury After Non-Cardiac Surgery in Urologic Cancer Patients(URO-MINS) | recruiting | — | 200 | Korea University Anam HospitalOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT07720284 | An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC(TU-04) | recruiting | Phase 3 | 915 | AstraZenecaINDUSTRY | 16 | Jul 22, 2026 | clinicaltrials |
| NCT06996782 | A Platform Study in Non-Small Cell Lung Cancer (NSCLC)(ALTAIR) | recruiting | Phase 1 / Phase 2 | 152 | AstraZenecaINDUSTRY | 20 | Jul 21, 2026 | clinicaltrials |
| NCT07218809 | AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer(TREVI-OC-01) | recruiting | Phase 3 | 1,100 | AstraZenecaINDUSTRY | 24 | Jul 21, 2026 | clinicaltrials |
| NCT07155226 | Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression(MOMENTUM) | recruiting | Phase 1 / Phase 2 | 84 | AstraZenecaINDUSTRY | 9 | Jul 20, 2026 | clinicaltrials |
| NCT06788990 | FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC(FORTIFI-HN01) | recruiting | Phase 2 / Phase 3 | 650 | Bicara TherapeuticsINDUSTRY | 26 | Jul 17, 2026 | clinicaltrials |
| NCT07710885 | Futibatinib (TAS-120) in Patients With Advanced Biliary Tract Cancer(FOENIX-BTC) | recruiting | Phase 3 | 784 | Taiho Pharmaceutical Co., Ltd.INDUSTRY | 4 | Jul 17, 2026 | clinicaltrials |
| NCT06906341 | Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers | recruiting | Phase 2 | 270 | Corcept TherapeuticsINDUSTRY | 8 | Jul 16, 2026 | clinicaltrials |
| NCT07306624 | Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer | recruiting | Phase 2 | 62 | STCube, Inc.INDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07010497 | A Prospective Study to Evaluate the Safety and Efficacy of the Combination Therapy of Irpagratinib, Atezolizumab, and Bevacizumab in Patients With Hepatocellular Carcinoma(IAPETUS) | recruiting | Phase 2 | 33 | Asan Medical CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07109219 | Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia(ALLight) | recruiting | Phase 1 / Phase 2 | 83 | AstraZenecaINDUSTRY | 9 | Jul 13, 2026 | clinicaltrials |
| NCT07699328 | A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer(REACH-EGFR) | recruiting | Phase 1 / Phase 2 | 315 | Voronoi, IncINDUSTRY | 10 | Jul 13, 2026 | clinicaltrials |
| NCT07699705 | Prospective Study of Ultrahypofractionated Proton Beam Therapy for Localized Prostate Cancer | recruiting | N/A | 50 | National Cancer Center, KoreaOTHER_GOV | 1 | Jul 13, 2026 | clinicaltrials |
| NCT06695845 | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | recruiting | Phase 2 | 200 | Jazz PharmaceuticalsINDUSTRY | 3 | Jul 10, 2026 | clinicaltrials |
| NCT06625593 | A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 168 | BeOne MedicinesINDUSTRY | 4 | Jul 9, 2026 | clinicaltrials |
| NCT07015697 | A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors | recruiting | Phase 1 | 76 | Daiichi SankyoINDUSTRY | 7 | Jul 9, 2026 | clinicaltrials |
| NCT06797986 | A Phase I/IIa Clinical Trial to Investigate BVAC-E6E7 in Subjects With HPV Positive HNSCC. | recruiting | Phase 1 / Phase 2 | 37 | Cellid Co., Ltd.INDUSTRY | 1 | Jul 8, 2026 | clinicaltrials |
| NCT07688356 | Belvarafenib for CNS Efficacy in Patients With BRAF-Altered Solid Tumors | recruiting | Phase 2 | 30 | Samsung Medical CenterOTHER | 1 | Jul 8, 2026 | clinicaltrials |
| NCT06796907 | A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors (BEHOLD-2) | recruiting | Phase 1 / Phase 2 | 305 | GlaxoSmithKlineINDUSTRY | 23 | Jul 7, 2026 | clinicaltrials |
| NCT02332668 | A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | recruiting | Phase 1 / Phase 2 | 370 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Jul 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials